Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Crizotinib
Drug ID BADD_D00535
Description Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status approved
ATC Code L01ED01
DrugBank ID DB08865
KEGG ID D09731
MeSH ID D000077547
PubChem ID 11626560
TTD Drug ID D03ZBT
NDC Product Code 68724-1020; 53869-2231; 53869-2230; 0069-8140; 0069-8141
UNII 53AH36668S
Synonyms Crizotinib | PF-02341066 | PF-2341066 | PF 2341066 | PF2341066 | PF 02341066 | PF02341066 | Xalkori
Chemical Information
Molecular Formula C21H22Cl2FN5O
CAS Registry Number 877399-52-5
SMILES CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Infantile vomiting07.01.07.010; 18.04.11.0040.000246%-
Sinus node dysfunction02.03.03.0170.000168%
Device related thrombosis08.07.05.001; 24.01.01.0270.000112%-
Brain neoplasm malignant16.30.04.002; 17.20.04.0020.000381%-
Bronchial carcinoma16.19.02.004; 22.08.01.0150.000470%-
Lung adenocarcinoma16.19.01.002; 22.08.01.0070.001903%-
Lung adenocarcinoma stage IV16.19.01.007; 22.08.01.0170.000168%-
Lung carcinoma cell type unspecified stage IV16.19.02.006; 22.08.01.0190.000246%-
Malignant pleural effusion16.32.03.014; 22.05.04.0010.000168%-
Neuroblastoma05.01.04.001; 16.30.03.002; 17.20.03.0020.000302%-
Non-small cell lung cancer stage IV16.19.01.010; 22.08.01.0220.000526%-
Normal pressure hydrocephalus17.07.01.0020.000112%-
Rectal perforation07.04.01.0040.000112%
Renal haematoma12.01.05.006; 20.01.02.018; 24.07.07.0040.000112%-
Subclavian vein thrombosis24.01.02.0130.000112%-
Metastases to meninges16.22.02.003; 17.02.10.0120.000112%-
Necrotising oesophagitis07.04.05.0060.000112%-
Biliary dilatation09.02.03.0040.000112%-
Cell death08.03.03.003; 14.11.02.0050.000168%-
Subacute cutaneous lupus erythematosus10.04.03.012; 15.06.02.012; 23.03.02.0200.000112%-
Gastrointestinal oedema07.11.01.0120.000224%-
Gastrointestinal amyloidosis07.11.01.024; 10.02.05.0040.000168%-
Non-small cell lung cancer metastatic16.19.01.009; 22.08.01.0210.000851%-
Renal cyst haemorrhage16.27.01.005; 20.01.04.017; 24.07.07.0030.000112%-
Embolic cerebral infarction17.08.01.029; 24.01.04.0090.000112%-
Diffuse alveolar damage22.01.01.0190.000168%-
Hypercreatininaemia14.11.01.039; 20.01.02.0160.000112%-
Age-related macular degeneration06.09.03.0180.000112%-
Inflammatory myofibroblastic tumour15.09.02.003; 16.33.08.0010.000112%-
Protein deficiency14.03.02.0230.000112%-
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene